NASDAQ:ALDRAlder Biopharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alder Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.88 0.00 (0.00 %) (As of 10/22/2019) Add Compare Share Today's Range$18.88Now: $18.88▼$18.8850-Day Range$18.88MA: $18.88▼$18.8852-Week Range$8.39Now: $18.88▼$19.12VolumeN/AAverage Volume5.12 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/ABeta2.64 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingAlder Biopharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.90, Alder Biopharmaceuticals has a potential upside of 0.1% from its current price of $18.88.Amount of Analyst CoverageAlder Biopharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAlder Biopharmaceuticals has received 414 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlder Biopharmaceuticals has received 346 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlder Biopharmaceuticals has received 54.47% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote “Outperform” if you believe ALDR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlder Biopharmaceuticals does not currently pay a dividend.Dividend GrowthAlder Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alder Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.40% of the stock of Alder Biopharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alder Biopharmaceuticals are expected to grow in the coming year, from ($3.92) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alder Biopharmaceuticals is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alder Biopharmaceuticals is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlder Biopharmaceuticals has a P/B Ratio of 11.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.87 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALDR Previous Symbol CUSIPN/A CIK1423824 Webwww.alderbio.com Phone425-205-2900Debt Debt-to-Equity Ratio1.74 Current Ratio8.94 Quick Ratio8.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.62 million Price / Sales977.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book11.73Profitability EPS (Most Recent Fiscal Year)($4.87) Net Income$-296,430,000.00 Net MarginsN/A Return on Equity-226.13% Return on Assets-66.86%Miscellaneous Employees202 Outstanding Shares83,840,000Market Cap$1.58 billion Next Earnings DateN/A OptionableOptionable Receive ALDR News and Ratings via Email Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter. Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Alder Biopharmaceuticals? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 8 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alder Biopharmaceuticals. How were Alder Biopharmaceuticals' earnings last quarter? Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the Zacks' consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' earnings history. What price target have analysts set for ALDR? 8 analysts have issued 1-year price targets for Alder Biopharmaceuticals' shares. Their forecasts range from $18.00 to $20.00. On average, they anticipate Alder Biopharmaceuticals' stock price to reach $18.90 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price. View analysts' price targets for Alder Biopharmaceuticals. Has Alder Biopharmaceuticals been receiving favorable news coverage? Media coverage about ALDR stock has trended very negative on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAlder Biopharmaceuticals. Who are some of Alder Biopharmaceuticals' key competitors? Some companies that are related to Alder Biopharmaceuticals include Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH) and Evotec (EVTCY). View all competitors. What other stocks do shareholders of Alder Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Celator Pharmaceuticals (CPXX), Celgene (CELG), Micron Technology (MU), Alibaba Group (BABA), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX) and Exelixis (EXEL). Who are Alder Biopharmaceuticals' key executives? Alder Biopharmaceuticals' management team includes the following people: Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)Mr. Carlos Campoy, Chief Financial Officer What is Alder Biopharmaceuticals' stock symbol? Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR." What is Alder Biopharmaceuticals' stock price today? One share of ALDR stock can currently be purchased for approximately $18.88. How big of a company is Alder Biopharmaceuticals? Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe. What is Alder Biopharmaceuticals' official website? The official website for Alder Biopharmaceuticals is www.alderbio.com. How can I contact Alder Biopharmaceuticals? Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected] This page was last updated on 5/26/2020 by MarketBeat.com Staff
